View
9
Download
0
Category
Preview:
Citation preview
193
References:
1. Overington JP, Al-Lazikani B, Hopkins AL. "How many drug targets
are there?" Nat Rev Drug Discov 5 (12), 2006, 993.
2. Filmore, David. "It's a GPCR world". Modern Drug Discovery. 2004,
24.
3. Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane
EJ, Saxena PR, Humphrey. "International Union of Pharmacology
classification of receptors for 5-hydroxytryptamine (Serotonin)".
Pharmacol. Rev. 46 (2), 1994, 157.
4. Frazer A, Hensler JG. "Chapter 13: Serotonin Receptors". In Siegel
GJ, Agranoff BW, Albers RW, Fisher SK, Uhler MD. "Basic
Neurochemistry: Molecular, Cellular, and Medical Aspects”.
Philadelphia: Lippincott-Raven. 1999, 263.
5. Nichols DE, Nichols CD. "Serotonin receptors". Chem. Rev. 108 (5),
2008, 1614.
6. Nagel B, Dellweg H, Gierasch LM. “Glossary for Chemists of the
terms used in biotechnology” Pure Appl. Chem. Vol. 64 (1), 1992,
143.
7. Schneider P, Tanrikulu Y, Schneider G. “Self-organizing maps in
drug discovery: compound library design, scaffold-hopping,
repurposing.” Curr Med Chem. 16 (3), 2009, 258.
194
8. Milligan G. "Constitutive activity and inverse agonists of G protein-
coupled receptors: a current perspective". Mol. Pharmacol. 64 (6),
2003, 1271.
9. Baaske P, Wienken CJ, Reineck P, Duhr S, Braun D. "Optical
Thermophoresis quantifies Buffer dependence of Aptamer Binding".
Angew. Chem. Int. Ed. 49 (12), 2010, 1.
10. Connolly CN, Wafford KA. "The Cys-loop superfamily of ligand-gated
ion channels: the impact of receptor structure on function". Biochem.
Soc. Trans. 32 (Pt3), 2004, 529.
11. Dudek RW. High-yield cell and molecular biology, Lippincott williams
& wilkins. 2006, 19.
12. Geuze HJ, Jan W. Slot JW, Peppard J, Figura KV, Hasilik A,
Schwartz AL “Intracellular receptor sorting during endocytosis:
Comparative immunoelectron microscopy of multiple receptors in rat
liver” Cell, 37 (1), 1984, 195.
13. Goodman and Gilman's Manual of Pharmacology and Therapeutics.
2008, 14.
14. Negus SS, "Some implications of receptor theory for in vivo
assessment of agonists, antagonists and inverse agonists". Biochem.
Pharmacol. 71 (12), 2006, 1663.
15. Gobeil F, “G-protein-coupled receptors signalling at the cell nucleus:
an emerging paradigm”. Can J Physiol Pharmacol. 84 (3 - 4), 2006,
287.
195
16. King N, Hittinger CT, Carroll SB. "Evolution of key cell signaling and
adhesion protein families predates animal origins". Science 301
(5631), 2003, 361.
17. Gilman AG. "G Proteins: Transducers of Receptor Generated
Signals". Annual Review of Biochemistry 56, 1987, 615.
18. Wettschureck N, Offermanns S. "Mammalian G proteins and their
cell type specific functions". Physiol. Rev., 85 (4), 2005, 1159.
19. Hallows KR, Alzamora R. "AMP-activated protein kinase inhibits
alkaline pH- and PKA-induced apical vacuolar H+-ATPase
accumulation in epididymal clear cells". Am. J. Physiol., Cell Physiol.
296 (4), 2009, C672.
20. Mellor H, Parker PJ. "The extended protein kinase C superfamily".
Biochem. J. 332 (Pt 2), 1998, 281.
21. Glennon RA, Dukat M, Westkaemper. "Serotonin Receptor Subtypes
and Ligands". American College of Neurophyscopharmacology. 2008.
22. Pazos A, Palacios JM. “Quantitative Autoradiographic Mapping of
Serotonin Receptors in the Rat Brain. I. Serotonin-1 Receptors”.
Brain Res. 346, 1985, 205.
23. Larsson LG, Rényi L, Ross SB, Svensson B, Angeby-Möller K.
"Different effects on the responses of functional pre- and
postsynaptic 5-HT1A receptors by repeated treatment of rats with the
5-HT1A receptor agonist 8-OH-DPAT". Neuropharmacology. 29 (2),
1990, 85.
196
24. Fornal CA, Metzler CW, Gallegos RA, Veasey SC, McCreary AC,
Jacobs BL. "WAY-100635, a potent and selective 5-
hydroxytryptamine1A antagonist, increases serotonergic neuronal
activity in behaving cats: comparison with (S)-WAY-100135". The
Journal of Pharmacology and Experimental Therapeutics. 278 (2),
1996, 752.
25. Yadav VK, Ryu JH, Suda N, Tanaka KF, Gingrich JA, Schütz G,
Glorieux FH, Chiang CY, Zajac JD, Insogna KL, Mann JJ, Hen R,
Ducy P, Karsenty G. "Lrp5 controls bone formation by inhibiting
serotonin synthesis in the duodenum". Cell 135 (5), 2008, 825.
26. Koe KB, Nielsen JA, Macor JE, Heym J. “Biochemical and behavioral
studies of the 5-HT1B receptor agonist, CP-94,253”. Drug
Development Research. 26 (3), 1992, 241.
27. Hudzik TJ, Yanek M, Porrey T, Evenden J, Paronis C, Mastrangelo M,
Ryan C, Ross S, Stenfors C. “Behavioral pharmacology of AR-
A000002, a novel, selective 5-hydroxytryptamine(1B) antagonist”.
Journal of Pharmacology and Experimental Therapeutics. 304 (3),
2003, 1072.
28. Glennon RA, Hong SS, Dukat M, Teitler M, Davis K. "5-(Nonyloxy)
tryptamine: a novel high-affinity 5-HT1D beta serotonin receptor
agonist". J. Med. Chem. 37 (18), 1994, 2828.
29. Easthope SE, Goa KL. Frovatriptan. CNS Drugs.15 (12), 2001, 969.
197
30. Schlicker E, Fink K, Molderings GJ, Price GW, Duckworth M, Gaster
L, Middlemiss DN, Zentner J, Likungu J, Göthert M. “Effects of
selective h5-HT1B (SB-216641) and h5-HT1D (BRL-15572) receptor
ligands on guinea-pig and human 5-HT auto- and heteroreceptors”.
Naunyn Schmiedebergs Archives of Pharmacology. 356 (3), 1997,
321.
31. Bai F, Yin T, Johnstone EM, Su C, Varga G, Little SP, Nelson DL.
"Molecular cloning and pharmacological characterization of the
guinea pig 5-HT1E receptor." European journal of pharmacology. 484
(2-3), 2004, 127.
32. John E. Macor & Martin J. Wythes, “Indole Derivatives” U.S. Patent
no. 5545644, August 13, 1996.
33. Monachon MA, Burkard WP, Jalfre M, Haefely W. "Blockade of
central 5-hydroxytryptamine receptors by methiothepin". Naunyn
Schmiedebergs Arch. Pharmacol. 274 (2), 1972, 192.
34. Adham N, Kao HT, Schecter LE, Bard J, Olsen M, Urquhart D,
Durkin M, Hartig PR, Weinshank RL, Branchek TA. "Cloning of
another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor
subtype coupled to the inhibition of adenylate cyclase". Proc. Natl.
Acad. Sci. U.S.A. 90 (2), 1993, 408.
35. Wainscott DB, Krushinski JH, Audia JE, Schaus JM, Zgombick JM,
Lucaites VL, Nelson DL. "[3H]-LY-334,370, a novel radioligand for the
198
5-HT1F receptor. In vitro characterization of binding properties".
Naunyn Schmiedebergs Arch. Pharmacol. 371 (3), 2005, 169.
36. Eison AS, Mullins UL. "Regulation of central 5-HT2A receptors: a
review of in vivo studies". Behavioural Brain Research. 73 (1–2),
1996, 177.
37. Cook EH, Fletcher KE, Wainwright M, Marks N, Yan SY, Leventhal
BL. "Primary structure of the human platelet serotonin 5-HT2
receptor: identity with frontal cortex serotonin 5-HT2A receptor". J.
Neurochem. 63 (2), 1994, 465.
38. Passie T, Halpern JH, Stichtenoth DO, Emrich HM, Hintzen A. "The
Pharmacology of Lysergic Acid Diethylamide: a Review". CNS
Neuroscience & Therapeutics. 14 (4), 2008, 295.
39. Akhondzadeh S, Malek-Hosseini M, Ghoreishi A, Raznahan M,
Rezazadeh SA. "Effect of ritanserin, a 5HT2A/2C antagonist, on
negative symptoms of schizophrenia: A double-blind randomized
placebo-controlled study". Progress in neuro-psychopharmacology &
biological psychiatry. 32 (8), 2008, 1879.
40. Callebert J, Esteve JM, Hervé P, Peoc'h K, Tournois C, Drouet L,
Launay JM, Maroteaux L. "Evidence for a control of plasma serotonin
levels by 5-hydroxytryptamine (2B) receptors in mice". J. Pharmacol.
Exp. Ther. 317 (2), 2006, 724.
199
41. Kennett GA, Bright F, Trail B, Baxter GS, Blackburn TP. "Effects of
the 5-HT2B receptor agonist, BW 723C86, on three rat models of
anxiety". British journal of pharmacology. 117 (7), 1996, 1443.
42. Bonhaus DW, Flippin LA, Greenhouse RJ, Jaime S, Rocha C,
Dawson M, Van Natta K, Chang LK, Pulido-Rios T, Webber A, Leung
E, Eglen RM, Martin GR. “RS-127445: a selective, high affinity, orally
bioavailable 5-HT2B receptor antagonist”. British Journal of
Pharmacology. 127 (5), 1999, 1075.
43. Alex KD, Yavanian GJ, McFarlane HG, Pluto CP, Pehek EA.
"Modulation of dopamine release by striatal 5-HT2C receptors".
Synapse. 55 (4), 2005, 242.
44. Heisler LK, Zhou L, Bajwa P, Hsu J, Tecott LH (July). "Serotonin 5-
HT2C receptors regulate anxiety-like behavior". Genes, Brain and
Behavior. 6 (5), 2007, 491.
45. Fletcher PJ, Rizos Z, Sinyard J, Tampakeras M, Higgins GA. “The 5-
HT2C receptor agonist Ro60-0175 reduces cocaine self-administration
and reinstatement induced by the stressor yohimbine, and
contextual cues”. Neuropsychopharmacology. 33 (6), 2008, 1402.
46. Kennett GA, Wood MD, Bright F, Trail B, Riley G, Holland V, Avenell
KY, Stean T. "SB 242084, a selective and brain penetrant 5-HT2C
receptor antagonist". Neuropharmacology. 36 (4-5), 1997, 609.
47. Yakel JL, Endo M, Kurachi Y, Mishina M. “The 5-HT3 receptor
channel: function, activation and regulation in Pharmacology of Ionic
200
Channel Function: Activators and Inhibitors (Handbook of
Experimental Pharmacology)”. 147, Berlin: Springer-Verlag, 2000,
541.
48. Dukat M, Young R, Darmani NN, Ahmed B, Glennon RA. "The 5-HT3
agent N-(3-chlorophenyl) guanidine (MD-354) serves as a
discriminative stimulus in rats and displays partial agonist character
in a shrew emesis assay". Psychopharmacology. 150 (2), 2000, 200.
49. PRNewswire. FDA Approves Granistron (Sancuso), the First and Only
Patch for Preventing Nausea and Vomiting in Cancer Patients
Undergoing Chemotherapy. September 12, 2008.
50. Hegde SS, Eglen RM. "Peripheral 5-HT4 receptors". The FASEB
journal. 10 (12), 1996, 1398.
51. Lucas G, Rymar VV, Du J, Mnie-Filali O, Bisgaard C, Manta S,
Lambas-Senas L, Wiborg O, Haddjeri N, Piñeyro G, Sadikot AF,
Debonnel G. "Serotonin (4) (5-HT (4)) Receptor Agonists Are Putative
Antidepressants with a Rapid Onset of Action.” Neuron. 55 (5), 2007,
712.
52. Birkeland JA. “Effects of treatment with a 5-HT4 receptor antagonist
in heart failure”. Br J Pharmacol. 150 (2), 2007, 143.
53. Francken BJ, Jurzak M, Vanhauwe JF, Luyten WH, Leysen JE. "The
human 5-ht5A receptor couples to Gi/Go proteins and inhibits
adenylate cyclase in HEK 293 cells". Eur. J. Pharmacol. 361 (2-3),
1998, 299.
201
54. Thomas DR, Soffin EM, Roberts C, Kew JN, Flor RM, Dawson LA, Fry
VA, Coggon SA, Faedo S, Hayes PD, Corbett DF, Davies CH, Hagan
JJ. “SB-699551-A (3-cyclopentyl-N-[2-(dimethylamino) ethyl]-N-[(4'-
{[(2-phenylethyl) amino] methyl}-4-biphenylyl) methyl] propanamide
dihydrochloride), a novel 5-ht5A receptor-selective antagonist,
enhances 5-HT neuronal function: Evidence for an autoreceptor role
for the 5-ht5A receptor in guinea pig brain”. Neuropharmacology.
51(3), 2006, 566.
55. Woolley ML, Marsden CA, Fone KC. "5-HT6 receptors". Current Drug
Targets. CNS and Neurological Disorders. 3 (1), 2004, 59.
56. Gérard C, Martres MP, Lefèvre K. "Immuno-localization of serotonin
5-HT6 receptor-like material in the rat central nervous system". Brain
Research. 746 (1-2), 1997, 207.
57. Hamon M, Doucet E, Lefèvre K. "Antibodies and antisense
oligonucleotide for probing the distribution and putative functions of
central 5-HT6 receptors".Neuropsychopharmacology. 21 (2), 1999,
68S.
58. Dawson LA, Nguyen HQ. "In vivo effects of the 5-HT (6) antagonist
SB-271046 on striatal and frontal cortex extracellular concentrations
of noradrenaline, dopamine, 5-HT, glutamate and aspartate". British
Journal of Pharmacology. 130 (1), 2000, 23.
59. Dawson LA, Nguyen HQ. "The 5-HT (6) receptor antagonist SB-
271046 selectively enhances excitatory neurotransmission in the rat
202
frontal cortex and hippocampus". Neuropsychopharmacology. 25 (5),
2001, 662.
60. King MV, Sleight AJ, Woolley ML, Topham IA, Marsden CA, Fone KC.
"5-HT6 receptor antagonists reverse delay-dependent deficits in novel
object discrimination by enhancing consolidation an effect sensitive
to NMDA receptor antagonism". Neuropharmacology. 47 (2), 2004,
195.
61. Orlacchio A, Kawarai T, Paciotti E. "Association study of the 5-
hydroxytryptamine (6) receptor gene in Alzheimer's disease."
Neurosci. Lett. 325 (1), 2002, 13.
62. Schechter LE, Lin Q, Smith DL. "Neuropharmacological profile of
novel and selective 5-HT6 receptor agonists: WAY-181187 and WAY-
208466". Neuropsychopharmacology. 33 (6), 2008, 1323.
63. Lacroix LP, Dawson LA, Hagan JJ, Heidbreder CA. "5-HT6 receptor
antagonist SB-271046 enhances extracellular levels of monoamines
in the rat medial prefrontal cortex". Synapse. 51 (2), 2004,158.
64. King MV, Marsden CA, Fone KC. "A role for the 5-HT (1A), 5-HT4 and
5-HT6 receptors in learning and memory". Trends in Pharmacological
Sciences. 29 (9), 2008, 482.
65. Arnt J, Bang-Andersen B, Grayson B, Bymaster FP, Cohen MP,
DeLapp NW, Giethlen B, Kreilgaard M, McKinzie DL, Neill JC, Nelson
DL, Nielsen SM, Poulsen MN, Schaus JM, Witten LM. “Lu AE58054,
a 5-HT (6) antagonist, reverses cognitive impairment induced by
203
subchronic phencyclidine in a novel object recognition test in rats”.
Int J Neuropsychopharmacol. 13(8), 2010, 1021.
66. Maher-Edwards G, Zvartau-Hind M, Hunter AJ. "Double-Blind,
Controlled Phase II Study of a 5-HT6 Receptor Antagonist, SB-
742457, in Alzheimer's Disease". Current Alzheimer Research. 7 (5),
2010, 374.
67. Nicola C, Sandrine A, Mark J, Michael W, Jesse C, Bruno V.
“Suitability of the Clinical Dementia Rating-Sum of Boxes as a single
primary endpoint for Alzheimer’s disease trials”. Alzheimer’s
Dementia 7 (6), 2011, 593.
68. Shacham S, Heal DJ, Cheetham SC, Jackson HC, Melendez R,
Rutkowski JV, Orbach P & Gannon KS. “PRX-07034, a Potent and
Selective 5-HT6 Receptor Antagonist, Reduces Food Intake and Body
Weight in Rats" Society for Neuroscience, Washington, DC, 2006.
69. Heal DJ, Smith SL, Fisas A, Codony X, Buschmann H. "Selective 5-
HT6 receptor ligands: progress in the development of a novel
pharmacological approach to the treatment of obesity and related
metabolic disorders". Pharmacol Ther. 117 (2), 2008, 207.
70. Frassetto A, Zhang J, Lao JZ. "Reduced sensitivity to diet-induced
obesity in mice carrying a mutant 5-HT6 receptor". Brain Research.
1236, 2008, 140.
204
71. Schechter LE, Lin Q, Smith DL. "Neuropharmacological profile of
novel and selective 5-HT6 receptor agonists: WAY-181187 and WAY-
208466". Neuropsychopharmacology. 33 (6), 2008, 1323.
72. Mattsson C, Sonesson C, Sandahl A, Greiner HE, Gassen M,
Plaschke J, Leibrock J, Böttcher H. "2-Alkyl-3-(1, 2, 3, 6-
tetrahydropyridin-4-yl)-1H-indoles as novel 5-HT6 receptor agonists".
Bioorg. Med. Chem. Lett. 15 (19), 2005, 4230.
73. Abate C, Kolanos R, Dukat M, Setola V, Roth BL, Glennon RA.
"Interaction of chiral MS-245 analogs at h5-HT6 receptors".
Bioorganic & medicinal chemistry letters. 15 (15), 2005, 3510.
74. Jasti V, Ramakrishna VSN, Kambhampati RS, Shirsath VS,
Vishwottam NK. “Preparation of pyrrolidinyl indoles as 5HT6 receptor
modulators” PCT Int.Appl. WO 2005066157; Chem.Abstr.143:
153282, 2005.
75. Cole DC, Ellingboe JW, Mazandarani H, Smith DL, Stock JR, Zhon P,
Schechter LE. “N1-Arylsulfonyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-
indole derivatives are potent and selective 5-HT6 receptor
antagonists”. Bioorg. Med. Chem. Lett. 15, 2005, 379.
76. Ramakrishna VSN, Shirasath VS, Kambhampati RS, Despande AD,
Daultabad AV, Vishwakarma S, Jasti V. “3-(Heterocyclyl)-N-
(arylsulfonyl) indole derivatives as functional 5-HT6 ligands” PCT Int.
Appl., WO 2007138611; Chem.Abstr. 148:33622, 2007.
205
77. Ramakrishna NVS, Kambhampati RS, Despande AD. Jasti V. “4-
(Heterocyclyl) alkyl-N-(arylsulfonyl) indole compounds and their use
of 5-HT6 ligands” PCT Int. Appl., WO 2008084491; Chem Abstr.
149:176374, 2009.
78. Ramakrishna NVS, Kambhampati RS, Shirasath VS, Jasti V. “N-
Arylsulfonyl-3-substituted indoles having serotonin receptor affinity,
process for their preparation and pharmaceutical composition
containing them” International Patent application WO 2004/048330,
2004.
79. Ruat M, Traiffort E, Leurs R, Tardivel-Lacombe J, Diaz J, Arrang JM,
Schwartz JC. "Molecular cloning, characterization, and localization of
a high-affinity serotonin receptor (5-HT7) activating cAMP formation".
Proc. Natl. Acad. Sci. U.S.A. 90 (18), 1993, 8547.
80. Meneses A, Perez-Garcia G, Liy-Salmeron G, Flores-Galvez D,
Castillo C, Castillo E. "The effects of the 5-HT (6) receptor agonist
EMD and the 5-HT (7) receptor agonist AS19 on memory formation".
Behavioural brain research. 195 (1), 2008, 112.
81. Abbas AI, Hedlund PB, Huang XP, Tran TB., Meltzer HY, Roth BL.
"Amisulpride is a potent 5-HT7 antagonist: relevance for
antidepressant actions in vivo". Psychopharmacology (Berl.). 205 (1),
2009, 119.
82. Davies SL, Silvestre JS, Guitart X. “Drug discovery targets”.
Drugs Future. 30, 2005, 479.
206
83. Slassi A, Isaac M, O'Brien A. “Recent progress in 5-HT6 receptor
antagonists for the treatment of CNS diseases”. Expert Opin. Ther.
Pat. 12, 2002, 513.
84. Monsma FJ, Shen Y, Ward RP, Hamblin MW, Sibley DR. “Cloning
and expression of a novel serotonin receptor with high affinity for
tricyclic psychotropic drugs”. Mol. Pharmacol. 43, 1993, 320.
85. Boess, FG, Riemer C, Bos M, Bentley J, Bourson A,Sleight AJ. “The
5-hydroxytryptamine-6 receptor-selective radioligand [3H] Ro 63-
0563 labels 5-hydroxytryptamine receptor binding sites in rat and
porcine striatum”. Mol. Pharmacol. 54, 1998, 577.
86. Kohen R, Metcalf MA, Khan N, Druck T, Huebner K, Lachowicz JE,
Meltzer HY, Sibley DR, Roth BL, Hamblin MW. “Cloning,
characterization, and chromosomal localization of a human 5-HT6
serotonin receptor”. J. Neurochem. 66, 1996, 47.
87. Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ , Shen Y,
Meltzer HY, Sibley DR. “Binding of typical and atypical antipsychotic
agents to 5-hydroxytryptamine-6 and 5- hydroxytryptamine-7
receptors”. J. Pharmacol. Exp. Ther. 268, 1994, 1403.
88. Glatt CE, Snowman AM, Sibley DR, Snyder SH. “Clozapine: selective
labeling of sites resembling 5-HT6 serotonin receptors may reflect
psychoactive profile”. Mol. Med, 1, 1995, 398.
89. Bourson A, Borroni E, Austin RH, Monsma FJ, Sleight AJ.
“Determination of the role of the 5-HT6 receptor in the rat brain: a
207
study using antisense oligonucleotides”. J. Pharmacol. Exp. Ther.
274, 1995, 173.
90. Yoshioka M, Matsumoto M, Togashi H, Mori K. “Central distribution
and function of 5-HT6 receptor subtype in the rat brain”. Ann. N. Y.
Acad Sci. 861, 1998, 244.
91. Woolley ML, Bentley JC, Sleight AJ, Marsden CA, Fone KC. “A role
for 5-HT6 receptors in retention of spatial learning in the Morris
water maze”. Neuropharmacology. 41, 2001, 210.
92. Bentley JC, Bourson A, Boess FG, Fone KC, Marsden CA, Petit N,
Sleight AJ. “Investigation of stretching behaviour induced by the
selective 5-HT6 receptor antagonist, Ro 04-6790, in rats”. Br. J.
Pharmacol. 126, 1999, 1537.
93. Sleight AJ, Boess FG, Bos M, Levet-Trafit B, Riemer C, Bourson A.
“Characterization of Ro 04-6790 and Ro 63-0563: potent and
selective antagonists at human and rat 5-HT6 receptors”. Br. J.
Pharmacol. 124, 1998, 556.
94. Bromidge SM, Brown AM, Clarke SE, Dodgson K, Gager T, Grassam
HL, Jeffrey PM, Joiner GF, King FD, Middlemiss DN, Moss SF,
Newman H, Riley G, Routledge C, Wyman P. “5- Chloro-N-(4-
methoxy-3-piperazin-1- yl- phenyl)-3-methyl-2-
benzothiophenesulfon- amide (SB-271046): a potent, selective, and
orally bioavailable 5-HT6 receptor antagonist”. J. Med. Chem. 42,
1999, 202.
208
95. Routledge C, Bromidge SM, Moss SF, Price GW, Hirst W, Newman H,
Riley G, Gager T, Stean T, Upton N, Clarke SE, Brown AM,
Middlemiss DN. “Characterization of SB-271046: a potent, selective
and orally active 5-HT6 receptor antagonist”. Br. J. Pharmacol. 130,
2000, 1606.
96. Hirst WD, Stean TO, Rogers DC, Sunter D, Pugh P, Moss SF,
Bromidge SM, Riley G, Smith DR, Bartlett S, Heidbreder CA,
Atkins AR, Lacroix LP, Dawson LA, Foley AG, Regan CM, Upton N.
“SB-399885 is a potent, selective 5-HT6 receptor antagonist with
cognitive enhancing properties in aged rat water maze and novel
object recognition models”. Eur. J. Pharmacol. 553, 2006, 109.
97. Schreiber R, Vivian J, Hedley L, Szczepanski K, Secchi R L, Zuzow
M, van Laarhoven S, Moreau J L, Martin J R, Sik A, Blokland A.
“Effects of the novel 5-HT6 receptor antagonist Ro 4368554 in rat
models for cognition and sensorimotor gating”. Eur.
Neuropsychopharmacol. 17, 2007, 277.
98. Upton N, Chuang TT, Hunter AJ, Virley DJ. "5-HT6 receptor
antagonists as novel cognitive enhancing agents for Alzheimer's
disease". NeuroTherapeutics. 5 (3), 2008, 458.
99. Kuperberg G, Heckers S. “Schizophrenia and cognitive function”.
Curr. Opin. Neurobiol. 10, 2000, 205.
100. Lee KH, Brown WH, Egleston PN, Green RD, Farrow TF, Hunter MD,
Parks RW, Wilkinson D, Spence SA, Woodruff PW. “A functional
209
magnetic resonance imaging study of social cognition in
schizophrenia during an acute episode and after recovery”. Am. J.
Psychiatry. 163, 2006, 1926.
101. Loiseau F, Dekeyne A, Millan MJ. “Pro-cognitive effects of 5- HT6
receptor antagonists in the social recognition procedure in rats:
implication of the frontal cortex”. Psychopharmacology. 196, 2008,
93.
102. Mitchell ES, Hoplight BJ, Lear SP, Neumaier JF. “BGC20-761, a
novel tryptamine analog, enhances memory consolidation and
reverses scopolamine-induced memory deficit in social and
visuospatial memory tasks through a 5-HT6 receptormediated
mechanism”. Neuropharmacology. 50, 2006, 412.
103. Schaffhauser H, Mathiasen JR, DiCamillo A, Huffman MJ, Lu LD,
McKenna BA, Qian J, Marino MJ. “Dimebolin is a 5-HT6 antagonist
with acute cognition enhancing activities”. Biochem. Pharmacol. 78
(8), 2009, 1035.
104. Dawson LA, Nguyen HQ. “In vivo effects of the 5-HT (6) antagonist
SB-271046 on striatal and frontal cortex extracellular concentrations
of noradrenaline, dopamine, 5-HT, glutamate and aspartate”. Br. J.
Pharmacol. 130, 2000, 23.
105. Dawson LA, Nguyen HQ. “The 5-HT(6) receptor antagonist SB-
271046 selectively enhances excitatory neurotransmission in the rat
210
frontal cortex and hippocampus”. Neuropsychopharmacology. 25,
2001, 662.
106. Lacroix LP, Dawson LA, Hagan JJ, Heidbreder CA. “5- HT6 receptor
antagonist SB-271046 enhances extracellular levels of monoamines
in the rat medial prefrontal cortex”. Synapse. 51, 2004, 158.
107. Schechter LE, Lin Q, Smith DL, Zhang G, Shan Q, Platt B, Brandt M
R, Dawson LA, Cole D, Bernotas R, Robichaud A, Rosenzweig-Lipson
S, Beyer CE. “Neuropharmacological Profile of Novel and Selective 5-
HT (6) Receptor Agonists: WAY-181187 and WAY-208466”.
Neuropsychopharmacology. 33 (6), 2008, 1323.
108. Heal DJ, Smith SL, Fisas A, Codony X, Buschmann H. “Selective 5-
HT6 receptor ligands: progress in the development of a novel
pharmacological approach to the treatment of obesity and related
metabolic disorders”. Pharmacol. Ther. 117, 2008, 207.
109. Glennon RA, Bondarev M, Roth BL. “5-HT6 serotonin receptor
binding of indolealkylamines: a preliminary structure-affinity
investigation”. Med. Chem. Res. 9, 1999, 108.
110. Glennon RA, Lee M, Rangisetty JB, Dukat M, Roth BL, Savage JE,
McBride A, Rauser L, Hufeisen S, Lee DKH. “2-Substituted
Tryptamines: Agents with Selectivity for 5-HT6 Serotonin Receptors”.
J. Med. Chem. 43, 2000, 1011.
111. Tsai Y, Dukat M, Slassi A, MacLean N, Demchyshyn L, Savage JE,
Roth BL, Hufesein S, Lee M, Glennon RA. “N1-(
211
Benzenesulfonyl)tryptamines as novel 5-HT6 antagonists”. Bioorg.
Med. Chem. Lett. 10, 2000, 2295.
112. Russell MGN, Baker RJ, Barden L, Beer MS, Bristow L, Broughton H
B, Knowles M, McAllister G, Patel S, Castro JL. “N-
Arylsulfonylindole derivatives as serotonin 5-HT6 receptor ligands”. J.
Med. Chem. 44, 2001, 3881.
113. Cole DC, Stock JR, Lennox WJ, Bernotas RC, Ellingboe JW, Boikess
S, Coupet J, Smith DL, Leung L, Zhang GM, Feng X, Kelly MF,
Galante R, Huang P, Dawson LA, Marquis K, Rosenzweig-Lipson S,
Beyer CE, Schechter LE. “Discovery of N1-(6-chloroimidazo[2,1-
b][1,3]thiazole-5-sulfonyl) tryptamine as a potent, selective, and
orally active 5-HT(6) receptor agonist”. J. Med. Chem. 50, 2007,
5535.
114. Cole DC, Stock JR, Lennox WJ, Bernotas RC, Ellingboe JW, Leung L,
Smith D, Zhang G, Qian L, Dawson LA, Boikess S, Rosenzweig-
Lipson S, Beyer CE, Schechter LE. “Discovery of a potent, selective
and orally active 5-HT6 receptor agonist, WAY-181187”. Abstracts of
Papers, 230th ACS National Meeting, Washington, DC, United States,
Aug. 28-Sept. 1, 2005, MEDI-017.
115. Cole DC, Stock JR, Lennox WJ, Zhou P. “Preparation of
indolylalkylamines as 5-hydroxytryptamine-6 ligands”. WO A1
2003053433, 2003.
212
116. Holenz J, Pauwels PJ, Diaz JL, Merce R, Codony X, Buschmann H.
“Medicinal chemistry strategies to 5-HT6 receptor ligands as potential
cognitive enhancers and antiobesity agents”.Drug Discov. Today, 11,
2006, 283.
117. Liu KG, Robichaud AJ. “5-HT6 antagonists as potential treatment for
cognitive dysfunction”. Drug Dev. Res. 70, 2009, 145.
118. Fu JM. “Preparation of arylsulphonyl-substituted tetrahydro- and
hexahydrocarbazolamines as 5-HT6 receptor ligands”. WO A1
2003030901, 2003.
119. Fu JM. “Preparation of 5-(arylsulfonyl) indoles having 5-HT6 receptor
affinity for treatment of CNS disorders”. WO A1 2003011284, 2003.
120. Zhou P, Yan Y, Bernotas R, Harrison BL, Huryn D, Robichaud AJ,
Zhang GM, Smith DL, Schechter LE. “4- (2-Aminoethoxy)-N-
(phenylsulfonyl)indoles as novel 5-HT6 receptor ligands”. Bioorg. Med.
Chem. Lett. 15, 2005, 1393.
121. Kelly MG, Cole DC. “Preparation of 1-aryl- or 1-
alkylsulfonylheterocyclylbenzazoles as 5-hydroxytryptamine-6
ligands”. WO A2 2002036562, 2002.
122. Beard CC, Clark RD, Fisher LE, Harris RN, Repke DB. “Preparation
of new indole derivatives with 5-HT6 receptor affinity”. WO A1
2002098857, 2002.
123. Madera AM, Weikert RJ. “Preparation of 2,7-substituted indoles as 5-
HT6 modulators”. WO A1 2004026830, 2004.
213
124. Madera AM, Weikert RJ. “Preparation of 2,7-substituted indoles as 5-
HT6 modulators”. WO A1 2004026831, 2004.
125. Holenz J, Merce R, Diaz JL, Guitart X, Codony X, Dordal A, Romero
G, Torrens A, Mas J, Andaluz B, Hernandez S, Monroy X, Sanchez
E, Hernandez E, Perez R, Cubi R, Sanfeliu O, Buschmann H.
“Medicinal chemistry driven approaches toward novel and selective
serotonin 5-HT6 receptor ligands”. J. Med. Chem. 48, 2005, 1781.
126. Filla SA, Flaugh ME, Gillig JR, Heinz LJ, Krushinski JH.
“Preparation of benzenesulfonic acid indol-5-yl esters as antagonists
of the 5-HT6 receptor”. WO A2 2002060871, 2002.
127. Pineiro-Nunez MM, Bauzon DD, Bymaster FP, Chen Z, Chernet E,
Clay MP, Crile R, DeLapp NW, Denny CP, Falcone JF, Flaugh ME,
Heinz LJ, Kiefer AD, Koch DJ, Krushinski JH, Leander JD,
Lindstrom TD, Liu B, McKinzie DL, Nelson DL, Phebus LA, Rocco V
P, Schaus JM, Wolff MC, Ward JS. “Discovery and SAR studies of
2,6-difluorobenzenesulfonic acid 1-methyl-3-(1- methylpiperidin-4-
yl)-1H-indol-5-yl ester, a novel and potent 5- HT6 antagonist for the
treatment of cognitive deficit”. Abstracts of Papers, 229th ACS
National Meeting, San Diego, CA, United States, March 13-17, 2005,
MEDI-282.
128. Lopez-Rodriguez ML, Benhamu B, Sanz A, Pardo L, Campillo M. “A
three-dimensional pharmacophore model for 5-
hydroxytryptamine6 (5-HT6) receptor antagonists”. J. Med. Chem.
214
48, 2005, 4216.
129. Batcho AD, Leimgruber W. “Indoles from 2-methyl nitro benzene by
condensation with formamide acetal followed by reduction”Org.
Synth, 63, 1985, 214.
130. Batcho AD, Leimgruber W. “Process & intermediate for the
preparation of indoles from ortho nitro toulenes” U.S Patent
3,732,245 & U.S. Patent 3,976,639, 1973.
131. Kelly, Micheal, Gerard. “1-Aryl-or 1-alkylsulfonyl-hetrocyclbenzazoles
as 5-HT6 ligands” WO 02/36562 A2, 2002.
132. Beard, Collin Charles, Clark, Robin, Douglas, Fisher Lawrence
Emerson. “‘New indole derivatives with 5-HT6R affinity” WO
02/098857 A1, 2002.
133. Ellen W, Baxter, Allen B, Reitz. “Reductive Aminations of
Carbonyl Compounds with Borohydride and Borane Reducing
Agents” Organic Reactions. 1, 2002, 59.
134. Bromidge, Steven, Mark.”Compound useful in the treatments of CNS
disorder” WO 02/41889 A2, 2002.
135. Nyandege A, Kolanos R, Roth BL, Glennon RA, “Further studies on
the binding of N1-substituted tryptamines at h5-HT6 receptors”.
Bioorganic & Medicinal Chemistry Letters. 17, 2007, 1691.
136. Chang-Fong J, Jagadeesh BR, Dokat M, Setola V, Thomas R,
Roth B, Glennon RA. “1,2,3,4-Tetrahydrocarbazoles as 5-HT6
215
serotonin receptor ligands”. Bioorganic & Medicinal Chemistry Letters.
14 (8), 2004, 1961.
137. Gewald K, Schinke E, Böttcher H.“Gewald’s reaction mechanisim“
Ber. 99, 1966, 94.
138. Ming WD, Jun XU R, Feng CHEN Y. A Selective Synthesis of 2-
Alkylamino-5,6,7,8-tetrahydro-benzothieno[2,3-d]pyrimidin-
4(3H)-ones”. Chinese Chemical Letters. Vol. 16 (2), 2005, 189.
139. Sachin LS, Bhatnagar SP. “Efficient Niementowski synthesis of novel
derivatives of 1,2,9,11-tetrasubstituted-7H-
thieno[2’,3’:4,5]pyrimido[6,1-b]-quinazolin-7-one”. ARKIVOC. (xvii)
2008, 212.
140. Temple DL, Yevich JP, Covington RR, Hanning CA, Seidehmed RJ,
Mackey HK, Bartek MJ. “Synthesis of 3,4-Dihydro-4-oxothieno[2,3-
d]pyrimidine-2-carboxylates, a New Series of Orally Active Antiallergy
Agents”. Journal of Medicinal Chemistry. Vol. 22 (5), 1979, 505.
141. Fatma EM, Hanan A.S, Hassan M. “Synthesis of Some
Thienopyrimidine Derivatives”. Molecules. 11, 2006, 498.
142. Bhujyan MN, Khandker MD, Mizanur RMD, Kammrul HAR, Ismail H
MD, Abu MD. “Synthesis and antimicrobial evalution of some new
thienopyrimidine derivatives”. Acta Pharm. 56, 2006, 441.
143. Vallance P, Smart TG. "The future of pharmacology" British journal of
pharmacology. 147 (1), 2006, S304.
216
144. Balani SK, Miwa GT, Gan LS, Wu JT, Lee FW. "Strategy of utilizing in
vitro and in vivo ADME tools for lead optimization and drug
candidate selection". Curr Top Med Chem. 5 (11), 2005, 1033.
145. http://www.merckmanuals.com/professional/sec21/ch324/ch324d.
html“Volume of distribution (VD)”
146. Semple KT, Doick KJ, Jones KC, Burauel P, Craven A, Harms H.
“Defining bioavailability and bioaccessibility of contaminated soil
and sediment is complicated". Environ. Sci. Technol. 38 (12), 2004,
228A.
147. Tracy TS. "Pharmacokinetics". In Stitzel RE, Craig CF. Modern
pharmacology with clinical applications. Hagerstwon, MD:
Lippincott Williams & Wilkins. 2004, 49.
148. IUPAC, Compendium of Chemical Terminology, 2nd ed. (the "Gold
Book") 1997. Online corrected version: "biological halflife". 2006
149. Seldin DW. "The development of the clearance concept". J.
Nephrol. 17 (1), 2004, 166.
150. Aldo Rescigno. “Area under the curve and bioavailability”.
Pharmacological Research. Volume 42 (6), 2000, 539.
151. Ennaceur A, Aggleton JP. “The effects of neurotoxic lesions of the
perirhinal cortex combined to fornix transection on object
recognition memory in the rat”. Behav. Brain. Res. 88, 1997, 181.
152. Jayarajan P, Vishwakarma SL, Pendharkar VV, Sharma DC,
Shirsath VS, Ramakrishna NVS. “Effect of selective 5-HT6 receptor
217
antagonists in rodent models of learning”. Society for neuroscience
35th annual meeting, Washington, DC, Nov 12-16, 2005.
218
LIST OF PUBLICATIONS
1. “Novel and Potent 5-Piperazinyl Methyl-N1-aryl Sulfonyl Indole
Derivatives as 5-HT6 Receptor Ligands”
Ramakrishna V. S. Nirogi,*† Prabhakar Kothmirkar,† Ramasastri
Kambhampati,† Jagadish Babu Konda,† Sobhanadri Arepalli,†
Narasimhareddy G. Pamuleti,† Amol D. Deshpande,† Trinathreddy
Bandyala,† Anil K. Shinde,† and P. K. Dubey‡
ACS Med.Chem.Lett. 2010, 1, 340-344.
2. “Convenient and Efficient Synthesis of Some Novel Fused Thieno
Pyrimidines Using Gewald's Reaction”
Ramakrishna V. S. Nirogia, Rama Sastri Kambhampatia,
Prabhakar Kothmirkara, Sobhanadri Arepallia, Narasimha Reddy
G. Pamuletia, Anil K. Shindea & P. K. Dubeyb
Synthetic Communications, 41: 2835-2851, 2011.
3. Synthesis of novel (1-substituted benzenesulfonyl-1H-indol-5-yl)-
(4-substituted piperazin-1-yl)-methanone derivatives as 5-HT6R
ligands
Ramakrishna V. S. Nirogi1, Prabhakar Kothmirkar1,2, Anil K.
Shinde1*, Jagadish Babu K1, K. R. Sastry1 and P. K. Dubey2
Der Pharma Chemica, 2011, 3(3): 221-231.
Recommended